Brought to you by 
Pfizer gets rights to commercialize nonprescription version of AZ's Nexium
16 Aug 2012
Executive Summary
AstraZeneca PLC has licensed fellow Big Pharma Pfizer Inc. exclusive worldwide rights to commercialize an over-the-counter version of the blockbuster gastroesophageal reflux disease treatment Nexium (esomeprazole magnesium).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- OTC, Consumer
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Pfizer gets rights to commercialize nonprescription version of AZ's Nexium
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice